Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited-Reference-Cited by-同舟云学术

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

Published:2019-10-05 Issue:4 Volume:59 Page:519-530
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Bensalem Amina,Mulleman Denis,Paintaud Gilles,Azzopardi Nicolas,Gouilleux-Gruart Valérie,Cornec Divi,Specks Ulrich,Ternant David^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-019-00826-5.pdf

Reference48 articles.

1. Li J, Levi M, Charoin J-E, Frey N, Kheoh T, Ren S, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin’s lymphoma (NHL) patients. Blood. 2007;110(11):2371.

2. Rozman S, Grabnar I, Novakovic S, Mrhar A, Jezersek Novakovic B. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83(8):1782–90. https://doi.org/10.1111/bcp.13271 .

3. Tout M, Gagez AL, Lepretre S, et al. Influence of FCGR3A-158 V/F genotype and baseline CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO Group. Clin Pharmacokinet. 2017;56(6):635–47. https://doi.org/10.1007/s40262-016-0470-8 .

4. Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129(19):2616–23. https://doi.org/10.1182/blood-2016-10-744292 .

5. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785–92.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis;Biomedicine & Pharmacotherapy;2024-06

2. Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study;Frontiers in Pharmacology;2024-03-26

3. Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence;Kidney International Reports;2024-01

4. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

5. Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients;Joint Bone Spine;2023-09